GENMAB AS SP.ADR/1/10DK 1 (GE91) - Net Assets
Based on the latest financial reports, GENMAB AS SP.ADR/1/10DK 1 (GE91) has net assets worth €5.85 Billion EUR (≈ $6.84 Billion USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€12.87 Billion ≈ $15.05 Billion USD) and total liabilities (€7.03 Billion ≈ $8.21 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Explore GE91 cash flow conversion to assess how effectively this company generates cash.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €5.85 Billion |
| % of Total Assets | 45.42% |
| Annual Growth Rate | 14.69% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 3.78 |
GENMAB AS SP.ADR/1/10DK 1 - Net Assets Trend (2021–2025)
This chart illustrates how GENMAB AS SP.ADR/1/10DK 1's net assets have evolved over time, based on quarterly financial data. Explore GENMAB AS SP.ADR/1/10DK 1 (GE91) long-term investment share to see how much of total assets are deployed in long-term investments.
Annual Net Assets for GENMAB AS SP.ADR/1/10DK 1 (2021–2025)
The table below shows the annual net assets of GENMAB AS SP.ADR/1/10DK 1 from 2021 to 2025. For live valuation and market cap data, see GE91 market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €5.85 Billion ≈ $6.84 Billion |
+14.20% |
| 2024-12-31 | €5.12 Billion ≈ $5.99 Billion |
+9.09% |
| 2023-12-31 | €4.69 Billion ≈ $5.49 Billion |
+19.52% |
| 2022-12-31 | €3.93 Billion ≈ $4.59 Billion |
+16.21% |
| 2021-12-31 | €3.38 Billion ≈ $3.95 Billion |
-- |
Equity Component Analysis
This analysis shows how different components contribute to GENMAB AS SP.ADR/1/10DK 1's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 168.7% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €4.10 Billion | 70.09% |
| Other Components | €1.75 Billion | 29.91% |
| Total Equity | €5.85 Billion | 100.00% |
GENMAB AS SP.ADR/1/10DK 1 Competitors by Market Cap
The table below lists competitors of GENMAB AS SP.ADR/1/10DK 1 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Banco Santander Chile
SN:BSANTANDER
|
$15.13 Billion |
|
Yunnan Aluminium Co Ltd
SHE:000807
|
$15.14 Billion |
|
Bank of Baroda
NSE:BANKBARODA
|
$15.15 Billion |
|
HAIER SM.HME UNSP.ADR/4
F:HAI0
|
$15.17 Billion |
|
Banco de Chile
F:G4RA
|
$15.05 Billion |
|
Ball Corporation
NYSE:BALL
|
$15.05 Billion |
|
Formosa Petrochemical Corp
TW:6505
|
$15.04 Billion |
|
Mueller Industries Inc
NYSE:MLI
|
$15.01 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in GENMAB AS SP.ADR/1/10DK 1's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 5,119,844,857 to 5,847,000,000, a change of 727,155,143 (14.2%).
- Net income of 963,000,000 contributed positively to equity growth.
- Share repurchases of 430,000,000 reduced equity.
- New share issuances of 5,500,000,000 increased equity.
- Other factors decreased equity by 5,305,844,857.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €963.00 Million | +16.47% |
| Share Repurchases | €430.00 Million | -7.35% |
| Share Issuances | €5.50 Billion | +94.07% |
| Other Changes | €-5.31 Billion | -90.74% |
| Total Change | €- | 14.20% |
Book Value vs Market Value Analysis
This analysis compares GENMAB AS SP.ADR/1/10DK 1's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.25x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 0.46x to 0.25x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €51.42 | €23.80 | x |
| 2022-12-31 | €60.07 | €23.80 | x |
| 2023-12-31 | €71.84 | €23.80 | x |
| 2024-12-31 | €80.58 | €23.80 | x |
| 2025-12-31 | €94.92 | €23.80 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently GENMAB AS SP.ADR/1/10DK 1 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 16.47%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 25.89%
- • Asset Turnover: 0.29x
- • Equity Multiplier: 2.20x
- Recent ROE (16.47%) is below the historical average (17.07%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 13.32% | 35.13% | 0.34x | 1.11x | €112.26 Million |
| 2022 | 19.98% | 37.59% | 0.48x | 1.10x | €392.03 Million |
| 2023 | 13.44% | 26.40% | 0.46x | 1.12x | €161.68 Million |
| 2024 | 22.13% | 36.30% | 0.49x | 1.25x | €621.02 Million |
| 2025 | 16.47% | 25.89% | 0.29x | 2.20x | €378.30 Million |
Industry Comparison
This section compares GENMAB AS SP.ADR/1/10DK 1's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $223,512,703
- Average return on equity (ROE) among peers: -29.10%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| GENMAB AS SP.ADR/1/10DK 1 (GE91) | €5.85 Billion | 13.32% | 1.20x | $15.06 Billion |
| PROQR THERAPEUTICS EO-04 (0PQ) | $49.37 Million | -85.44% | 1.28x | $142.34 Million |
| TIZIANA LIFE SCIENCES LTD (0RP) | $41.28 Million | -56.73% | 0.18x | $161.62 Million |
| Theravance Biopharma Inc (0TB) | $-303.75 Million | 0.00% | 0.00x | $823.46 Million |
| I-MAB SPONS.ADS/1 -0001 (0VY) | $715.33 Million | -51.14% | 0.23x | $212.27 Million |
| PreveCeutical Medical Inc (18H) | $-4.49 Million | 0.00% | 0.00x | $3.34 Million |
| Argen-X (1AE) | $344.93 Million | -8.14% | 0.08x | $41.67 Billion |
| WAVE LIFE SCIENCES LTD. (1U5) | $518.36 Million | -39.43% | 0.23x | $1.14 Billion |
| BIOCURE TECHNOLOGY INC. (1WH) | $1.34 Million | -19.58% | 0.49x | $960.84K |
| ZAI LAB LTD0000006 (1ZLB) | $840.90 Million | -30.57% | 0.41x | $1.82 Billion |
| BioNTech SE (22UA) | $31.86 Million | 0.00% | 11.24x | $20.05 Billion |
About GENMAB AS SP.ADR/1/10DK 1
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervi… Read more